Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 21-30 of 38 (Search time: 0.003 seconds).
previous
1
2
3
4
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford, S.
;
Vaz de Melo, J.
;
Hughes, T.
2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Muller, M.
;
Cortes, J.
;
Kim, D.
;
Druker, B.
;
Erben, P.
;
Pasquini, R.
;
Branford, S.
;
Hughes, T.
;
Radich, J.
;
Ploughman, L.
;
Mukhopadhyay, J.
;
Hochhaus, A.
2005
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A.
;
Cambareri, A.
;
Zannettino, A.
;
Boog, B.
;
Doherty, K.
;
Hughes, T.
;
Lyons, A.
2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Branford, S.
;
Yeung, D.
;
Prime, J.
;
Choi, S.
;
Bang, J.
;
Park, J.
;
Kim, D.
;
Ross, D.
;
Hughes, T.
2011
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Cortes, J.
;
Hochhaus, A.
;
Hughes, T.
;
Kantarjian, H.
2009
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Baccarani, M.
;
Cortes, J.
;
Pane, F.
;
Niederwieser, D.
;
Saglio, G.
;
Apperley, J.
;
Cervantes, F.
;
Deininger, M.
;
Gratwohl, A.
;
Guilhot, F.
;
Hochhaus, A.
;
Horowitz, M.
;
Hughes, T.
;
Kantarjian, H.
;
Larson, R.
;
Radich, J.
;
Simonsson, B.
;
Silver, R.
;
Goldman, J.
;
Hehlmann, R.
2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?
Fitter, S.
;
Vandyke, K.
;
Schultz, C.
;
White, D.
;
Hughes, T.
;
Zannettino, A.
2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Tang, M.
;
Gonen, M.
;
Quintas-Cardama, A.
;
Cortes, J.
;
Kantarjian, H.
;
Field, C.
;
Hughes, T.
;
Branford, S.
;
Michor, F.
2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Venables, A.
;
Zrim, S.
;
Zannettino, A.
;
Lynch, K.
;
Manley, P.
;
Hughes, T.
2013
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects
Vandyke, K.
;
Fitter, S.
;
Drew, J.
;
Fukumoto, S.
;
Schultz, C.
;
Sims, N.
;
Yeung, D.
;
Hughes, T.
;
Zannettino, A.
Discover
Author
13
White, D.
11
Hochhaus, A.
9
Branford, S.
9
Radich, J.
9
Saglio, G.
8
Kantarjian, H.
7
Cortes, J.
5
Guilhot, F.
5
Kim, D.
5
Larson, R.
.
next >
Subject
34
Humans
33
Pyrimidines
29
Leukemia, Myelogenous, Chronic, B...
25
Benzamides
25
Piperazines
24
Imatinib Mesylate
20
Antineoplastic Agents
13
Fusion Proteins, bcr-abl
12
Treatment Outcome
10
Dasatinib
.
next >
Date issued
27
2010 - 2017
11
2005 - 2009